• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Perrigo Secures API Divestiture for $110M

contractpharmNovember 22, 2017

Tag: Perrigo , API

Perrigo Company has completed the divestiture of its active pharmaceutical ingredient (API) business based in Israel to SK Capital for $110 million. The company is also one of the world's largest manufacturers of over-the-counter (OTC) healthcare products and suppliers of infant formulas.

"Actions taken as part of this review process have enabled us to simplify, focus and execute on our core businesses. We continue to look at capital deployment opportunities that drive value for shareholders and further our mission of providing quality, affordable healthcare products to consumers around the globe," said Perrigo's chief executive officer, John T. 

Previous:Tiny Corbus Aims to Have Four Drugs in Mid- to Late-Stage Development by Next Year

Next:FDA approves first two-drug regimen for certain patients with HIV

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Perrigo Secures API Divestiture for $110M | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Apigenin 7-glucoside

Apigenin 7-glucoside
Tolvaptan ≥98.0% min Pharmaceutical API made in china

Tolvaptan ≥98.0% min Pharmaceutical API made in china
Rizatriptan benzoate ≥98.0% API Pharmaceutical made in china

Rizatriptan benzoate ≥98.0% API Pharmaceutical made in china
Terlipressin supplier API Pharmaceutical Polypeptide made in china

Terlipressin supplier API Pharmaceutical Polypeptide made in china
N-Demethyl Olanzapine

N-Demethyl Olanzapine
Voglibose 99%min supplier Pharmaceutical API Hypoglycemic agents made in china

Voglibose 99%min supplier Pharmaceutical API Hypoglycemic agents made in china
Apixaban

Apixaban
Apigenin

Apigenin
New machine for sale Rapid cool-down and heat-up Equipment SUNDI-725WN

New machine for sale Rapid cool-down and heat-up Equipment SUNDI-725WN
FMD series scraping film molecular distillation

FMD series scraping film molecular distillation

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service